Prognosis and cure of long‐term cancer survivors: A population‐based estimation

Cancer Medicine

AIRTUM Working group¹  Chiara Panato²  Riccardo Capocaccia²  Diego Serraino²  Luigino Dal Maso²  Rosario Tumino³  Mario Fusco⁴  Francesco Tisano⁵  Roberta De Angelis⁶  Laura Botta⁷  Anna Gigli⁸  Rosa Angela Filiberti⁹  Giovanna Tagliabue^1,10  Giuliano Carrozzi^1,11  Silvia Francisci^1,12  Andrea Tavilla^1,12  Rosaria Cesaraccio^1,13  Giovanna Maria Sini^1,14  Maria Michiara^1,15  Fabrizio Stracci^1,16  Antonietta Torrisi^1,17  Stefano Rosso^1,18  Emanuele Crocetti^1,19  Fabio Falcini^1,19  Stefano Ferretti^2,20  Anna Clara Fanetti^2,21  Guido Mazzoleni^2,22  Carlotta Buzzoni^2,23  Stefano Guzzinati^2,24  Massimo Rugge^2,24 

[1] ;Cancer Epidemiology Unit Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Aviano Italy;Cancer Registry ASP Ragusa Victoria Italy;Cancer Registry of ASL Napoli 3 Sud Napoli Italy;Cancer Registry of the Province of Siracusa Local Health Unit of Siracusa Siracusa Italy;Department of Oncology and Molecular Medicine Italian National Institute of Health (ISS) Rome Italy;Evaluative Epidemiology Unit, Department of Preventive and Predictive Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy;Institute for Research on Population and Social Policies National Research Council Rome Italy;Liguria Cancer Registry, Clinical Epidemiology IRCCS Policlinico San Martino Genova Italy;Lombardy Cancer Registry-Varese Province, Cancer Registry Unit, Department of Research Fondazione IRCCS Istituto Nazionale Tumori Milan Italy;Modena Cancer Registry, Public Health Department AUSL Modena Modena Italy;National Center for Prevention and Health Promotion Italian National Institute of Health (ISS) Rome Italy;North Sardinia Cancer Registry Azienda Regionale per la Tutela della Salute Sassari Italy;Nuoro Cancer Registry ASSL Nuoro/ATS Sardegna Nuoro Italy;Parma Cancer Registry, Oncology Unit Azienda Ospedaliera Universitaria di Parma Parma Italy;Public Health Section, Department of Experimental Medicine University of Perugia Perugia Italy;Registro Tumori Integrato Catania‐Messina‐Siracusa‐Enna Catania Italy;Registro Tumori Piemonte Provincia di Biella CPO Biella Italy;Romagna Cancer Registry Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS and Azienda Usl della Romagna Meldola (Forlì) Italy;Romagna Cancer Registry ‐ Section of Ferrara. Local Health Unit University of Ferrara Ferrara Italy;Sondrio Cancer Registry, Epidemiology unit ATS della Montagna Sondrio Italy;South‐Tyrol Tumor Registry Bolzano Italy;Tuscany Cancer Registry Clinical and Descriptive Epidemiology Unit, Cancer Prevention and Research Institute (ISPO) Florence Italy;Veneto Tumour Registry Azienda Zero Padua Italy;

关键词: cancer cure;    Italy;    population‐based cancer registries;    prevalence;    survival;   

DOI  :  10.1002/cam4.2276

来源: DOAJ

【 摘 要 】

Abstract Background Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population‐based indicators of cancer cure. Methods Information on more than half a million cancer patients aged 15‐74 years collected by population‐based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5‐year conditional relative survival (CRS) >90% or 95% (time to cure). Results Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.2 to 7.4 years). Median LEFT in 1990 was >5 years for testicular cancers (5.8) and Hodgkin lymphoma (6.3) below 45 years of age. In both sexes, it was ≤0.5 years for pancreatic cancers and NHL in 1990 and in 2000. The cure fraction showed a 10% increase between 1990 and 2000. It was 95% for thyroid cancer in women, 94% for testis, 75% for prostate, 67% for breast cancers, and <20% for liver, lung, and pancreatic cancers. Time to 5‐year CRS >95% was <10 years for testis, thyroid, colon cancers, and melanoma. For breast and prostate cancers, the 5‐year CRS >90% was reached in <10 years but a small excess remained for >15 years. Conclusions The study findings confirmed that several cancer types are curable. Became aware of the possibility of cancer cure has relevant clinical and social impacts.

【 授权许可】

Unknown